

Supplementary Material

Table of Contents

I. Supplementary Materials and Methods.....	2
Search strategy and results	
Risk of bias	
II. Supplementary Figures.....	13

I. Supplementary Materials and Methods

1. Search strategy and results

(1) Summary of search results

No.	DB	Results	Duplication
1	PubMed (Medline)	999	
2	EMBASE	1,717	
3	Cochrane Library	522	
4	Web of Science	567	1,256
5	KoreaMed	3	
Number of Search Results (including duplication)		3,808	
Number of Search Results (without duplication)		2,552	

(2) Keywords

PICO	Fields	Keywords	Remarks
P	MeSH	Breast neoplasms	A
	TIAB	Breast neoplasm*	B
	TIAB	Breast tumor*	
	TIAB	Breast carcinoma*	
	TIAB	Human mammary neoplasm*	
	TIAB	Breast cancer*	
	TIAB	Mammary neoplasm*	
	TIAB	Mammary cancer*	
	TIAB	Mammary carcinoma*	
	TIAB	Mammary tumor*	
	TIAB	Breast malignant neoplasm*	
	TIAB	Breast malignant tumor*	
	TIAB	Breast malignant cancer*	
	TIAB	Breast malignant carcinoma*	
		A OR B	C
I	MeSH	Tamoxifen	D
	MeSH	Toremifene	
	MeSH	Letrozole	
	MeSH	Anastrozole	

	MeSH	Antineoplastic agents, hormonal	
	MeSH	Selective estrogen receptor modulators	
	MeSH	Aromatase inhibitors	
	Supplementary Concept	Exemestane	E
	TIAB	Tamoxifen*	F
	TIAB	ICI-47699	
	TIAB	ICI47699	
	TIAB	Nolvadex	
	TIAB	Novaldex	
	TIAB	Tamoxifen citrate	
	TIAB	Tomaxithen	
	TIAB	Zitazonium	
	TIAB	ICI-46474	
	TIAB	ICI46474	
	TIAB	ICI-46,474	
	TIAB	ICI46,474	
	TIAB	Soltamox	
	TIAB	Crisafeno	
	TIAB	Toremifene	
	TIAB	Fareston	
	TIAB	FC-1157a	
	TIAB	FC1157a	
	TIAB	CGS-20267	
	TIAB	CGS20267	
	TIAB	Femara	
	TIAB	Letrozole	
	TIAB	Anastrozole	
	TIAB	Anastrozole	
	TIAB	ICI D1033	
	TIAB	ZD-1033	
	TIAB	ZD1033	
	TIAB	Arimidex	
	TIAB	Exemestane	
	TIAB	Examestane	
	TIAB	FCE 24304	
	TIAB	FCE24304	
	TIAB	Aromasin	
	TIAB	Hormonal antineoplast*	

	TIAB	Antineoplastic hormon*	G
	TIAB	SERM*	
	TIAB	Selective estrogen receptor modulator*	
	TIAB	Aromatase inhibitor*	
		D O R E O R F	
O	MeSH	Angina pectoris	H
	MeSH	Aortic valve stenosis	
	MeSH	Arrhythmias, cardiac	
	MeSH	Atherosclerosis	
	MeSH	Atrial fibrillation	
	MeSH	Cardiomyopathies	
	MeSH	Cardiovascular diseases	
	MeSH	Coronary artery disease	
	MeSH	Embolism	
	MeSH	Heart failure	
	MeSH	Myocardial infarction	
	MeSH	Myocardial ischemia	
	MeSH	Myocarditis	
	MeSH	Peripheral vascular diseases	
	MeSH	Stroke	
	MeSH	Thromboembolism	
	MeSH	Venous thromboembolism	
	MeSH	Heart diseases	
	TIAB	Acute stroke*	I
	TIAB	Angina	
	TIAB	Angor pectoris	
	TIAB	Aortic stenosis*	
	TIAB	Aortic valve stenosis*	
	TIAB	Apoplexy	
	TIAB	Arrhythmia	
	TIAB	Arrhythmia	
	TIAB	Atherogenesis	
	TIAB	Atherosclerosis*	
	TIAB	Atrial fibrillation*	
	TIAB	Auricular fibrillation*	
	TIAB	Brain vascular accident*	
	TIAB	Cardiac arrhythmia*	
	TIAB	Cardiac decompensation*	

	TIAB	Cardiac disease*
	TIAB	Cardiac dysrhythmia*
	TIAB	Cardiac event*
	TIAB	Cardiac failure
	TIAB	Cardiomyopath*
	TIAB	Cardiovascular disease*
	TIAB	Cardiovascular event*
	TIAB	Cardiovascular outcome*
	TIAB	Cardiovascular stroke*
	TIAB	Carditis
	TIAB	Cerebral stroke*
	TIAB	Cerebrovascular accident*
	TIAB	Cerebrovascular apoplexy
	TIAB	Cerebrovascular stroke*
	TIAB	Coronary arteriosclerosis*
	TIAB	Coronary artery disease*
	TIAB	Coronary atherosclerosis*
	TIAB	Embolism*
	TIAB	Embolus
	TIAB	Heart attack*
	TIAB	Heart decompensation*
	TIAB	Heart disease*
	TIAB	Heart event*
	TIAB	Heart failure
	TIAB	Ischaemic heart disease*
	TIAB	Ischemic heart disease*
	TIAB	Major adverse cardiac event*
	TIAB	Myocardial decompensation*
	TIAB	Myocardial disease*
	TIAB	Myocardial failure
	TIAB	Myocardial infarct*
	TIAB	Myocardial ischaemi*
	TIAB	Myocardial ischemi*
	TIAB	Myocardiopath*
	TIAB	Myocarditides
	TIAB	Myocarditis
	TIAB	Paroxysmal atrial
	TIAB	Peripheral angiopath*

	TIAB	Peripheral vascular disease*	
	TIAB	Stenocardia*	
	TIAB	Stroke*	
	TIAB	Thromboembolism*	
	TIAB	Transient ischaemi*	
	TIAB	Transient ischemi*	
		H OR I	J
		C AND G AND J	K

(3) Search strategy

DB	Search Strategy
PubMed	(("breast neoplasms"[MeSH Terms] OR ("breast neoplasm"[Title/Abstract] OR "breast tumor"[Title/Abstract] OR "breast carcinoma"[Title/Abstract] OR "human mammary neoplasm"[Title/Abstract] OR "breast cancer"[Title/Abstract] OR "mammary neoplasm"[Title/Abstract] OR "mammary cancer"[Title/Abstract] OR "mammary carcinoma"[Title/Abstract] OR "mammary tumor"[Title/Abstract] OR "breast malignant neoplasm"[Title/Abstract] OR "breast malignant tumor"[Title/Abstract])) AND ("tamoxifen"[MeSH Terms] OR "Toremifene"[MeSH Terms] OR "Letrozole"[MeSH Terms] OR "Anastrozole"[MeSH Terms] OR "antineoplastic agents, hormonal"[MeSH Terms] OR "selective estrogen receptor modulators"[MeSH Terms] OR "aromatase inhibitors"[MeSH Terms] OR "Exemestane"[Supplementary Concept] OR ("tamoxifen"[Title/Abstract] OR "ICI-47699"[Title/Abstract] OR "Nolvadex"[Title/Abstract] OR "Novaldex"[Title/Abstract] OR "Tamoxifen citrate"[Title/Abstract] OR "Zitazonium"[Title/Abstract] OR "ICI-46474"[Title/Abstract] OR "ICI46474"[Title/Abstract] OR "ICI-46,474"[Title/Abstract] OR "Soltamox"[Title/Abstract] OR "Crisafeno"[Title/Abstract] OR "Toremifene"[Title/Abstract] OR "Fareston"[Title/Abstract] OR "FC-1157a"[Title/Abstract] OR "FC1157a"[Title/Abstract] OR "CGS-20267"[Title/Abstract] OR "CGS20267"[Title/Abstract] OR "Femara"[Title/Abstract] OR "Letrozole"[Title/Abstract] OR "Anastrozole"[Title/Abstract] OR "Anastrozole"[Title/Abstract] OR "ICI D1033"[Title/Abstract] OR "ZD-1033"[Title/Abstract] OR "ZD1033"[Title/Abstract] OR "Arimidex"[Title/Abstract] OR "Exemestane"[Title/Abstract] OR "Examestane"[Title/Abstract] OR "FCE 24304"[Title/Abstract] OR "FCE24304"[Title/Abstract] OR "Aromasin"[Title/Abstract] OR "hormonal antineoplast"[Title/Abstract] OR "antineoplastic hormon"[Title/Abstract] OR "serm"[Title/Abstract] OR "selective estrogen receptor modulator"[Title/Abstract] OR "aromatase inhibitor"[Title/Abstract])) AND ("acute stroke"[Title/Abstract] OR "Angina"[Title/Abstract] OR "Angor pectoris"[Title/Abstract] OR "aortic stenosis"[Title/Abstract] OR "aortic valve stenosis"[Title/Abstract] OR "Apoplexy"[Title/Abstract] OR "Arrhythmia"[Title/Abstract] OR "Arrhythmia"[Title/Abstract] OR "Atherogenesis"[Title/Abstract] OR "atherosclerosis"[Title/Abstract] OR "atrial fibrillation"[Title/Abstract] OR "auricular fibrillation"[Title/Abstract] OR "brain vascular accident"[Title/Abstract] OR "cardiac arrhythmia"[Title/Abstract] OR "cardiac decompensation"[Title/Abstract] OR "cardiac disease"[Title/Abstract] OR "cardiac dysrhythmia"[Title/Abstract] OR "cardiac event"[Title/Abstract] OR "Cardiac failure"[Title/Abstract] OR "cardiomyopath"[Title/Abstract] OR "cardiovascular disease"[Title/Abstract] OR "cardiovascular event"[Title/Abstract] OR "cardiovascular outcome"[Title/Abstract] OR "cardiovascular stroke"[Title/Abstract] OR "Carditis"[Title/Abstract] OR "cerebral stroke"[Title/Abstract] OR "cerebrovascular accident"[Title/Abstract] OR "Cerebrovascular apoplexy"[Title/Abstract] OR "cerebrovascular stroke"[Title/Abstract] OR "coronary arteriosclerosis"[Title/Abstract] OR "coronary artery disease"[Title/Abstract] OR "coronary atherosclerosis"[Title/Abstract] OR "embolism"[Title/Abstract] OR "Embolus"[Title/Abstract] OR "heart attack"[Title/Abstract] OR "heart decompensation"[Title/Abstract] OR "heart disease"[Title/Abstract] OR "heart event"[Title/Abstract] OR "Heart failure"[Title/Abstract] OR "ischemic heart disease"[Title/Abstract] OR "ischemic heart disease"[Title/Abstract] OR "major adverse cardiac event"[Title/Abstract] OR "myocardial decompensation"[Title/Abstract] OR "myocardial disease"[Title/Abstract] OR "Myocardial failure"[Title/Abstract] OR "myocardial infarct"[Title/Abstract] OR "myocardial ischaemi"[Title/Abstract] OR "myocardial ischemi"[Title/Abstract] OR "myocardiopath"[Title/Abstract] OR "Myocarditides"[Title/Abstract] OR "Myocarditis"[Title/Abstract] OR "Paroxysmal atrial"[Title/Abstract] OR "peripheral angiopath"[Title/Abstract] OR "peripheral vascular

	<p>disease*[Title/Abstract] OR "stenocardia"[Title/Abstract] OR "stroke"[Title/Abstract] OR "thromboembolism"[Title/Abstract] OR "transient ischaemi"[Title/Abstract] OR "transient ischemi"[Title/Abstract] OR ("angina pectoris"[MeSH Terms] OR "aortic valve stenosis"[MeSH Terms] OR "arrhythmias, cardiac"[MeSH Terms] OR "atherosclerosis"[MeSH Terms] OR "atrial fibrillation"[MeSH Terms] OR "cardiomyopathies"[MeSH Terms] OR "cardiovascular diseases"[MeSH Terms] OR "coronary artery disease"[MeSH Terms] OR "embolism"[MeSH Terms] OR "Heart failure"[MeSH Terms] OR "myocardial infarction"[MeSH Terms] OR ("myocardial ischemia"[MeSH Terms] OR "coronary artery disease"[MeSH Terms]) OR "Myocarditis"[MeSH Terms] OR "peripheral vascular diseases"[MeSH Terms] OR "stroke"[MeSH Terms] OR "thromboembolism"[MeSH Terms] OR "venous thromboembolism"[MeSH Terms] OR "heart diseases"[MeSH Terms])) NOT ("animals"[MeSH Terms:noexp] NOT ("animals"[MeSH Terms:noexp] AND "humans"[MeSH Terms]))</p>
EMBASE	<p>((('breast tumor'/exp OR 'breast carcinoma'/exp OR 'breast cancer'/exp) OR ('breast neoplasm*':ab,ti OR 'breast tumor*':ab,ti OR 'breast carcinoma*':ab,ti OR 'human mammary neoplasm*':ab,ti OR 'breast cancer*':ab,ti OR 'mammary neoplasm*':ab,ti OR 'mammary cancer*':ab,ti OR 'mammary carcinoma*':ab,ti OR 'mammary tumor*':ab,ti OR 'breast malignant neoplasm*':ab,ti OR 'breast malignant tumor*':ab,ti OR 'breast malignant cancer*':ab,ti OR 'breast malignant carcinoma*':ab,ti)) AND ((('tamoxifen'/exp OR 'toremifene'/exp OR 'letrozole'/exp OR 'anastrozole'/exp OR 'selective estrogen receptor modulator'/exp OR 'aromatase inhibitor'/exp OR 'exemestane'/exp OR 'tamoxifen citrate'/exp OR 'antineoplastic hormone agonists and antagonists'/exp) OR (tamoxifen*':ab,ti OR 'ici 47699':ab,ti OR 'ici47699':ab,ti OR 'nolvadex':ab,ti OR 'tamoxifen citrate':ab,ti OR 'tomaxithen':ab,ti OR 'zitazonium':ab,ti OR 'ici-46474':ab,ti OR 'ici46474':ab,ti OR 'ici-46,474':ab,ti OR 'ici46,474':ab,ti OR 'soltamox':ab,ti OR 'crisafeno':ab,ti OR 'toremifene':ab,ti OR 'fareston':ab,ti OR 'fc-1157a':ab,ti OR 'fc1157a':ab,ti OR 'cgs-20267':ab,ti OR 'cgs20267':ab,ti OR 'femara':ab,ti OR 'letrozole':ab,ti OR 'anastrozole':ab,ti OR 'anastrozole':ab,ti OR 'ici d1033':ab,ti OR 'zd-1033':ab,ti OR 'zd1033':ab,ti OR 'arimidex':ab,ti OR 'exemestane':ab,ti OR 'examestane':ab,ti OR 'fce 24304':ab,ti OR 'fce24304':ab,ti OR 'aromasin':ab,ti OR 'hormonal antineoplast*':ab,ti OR 'antineoplastic hormon*':ab,ti OR 'serm*':ab,ti OR 'selective estrogen receptor modulator*':ab,ti OR 'aromatase inhibitor*':ab,ti)) AND ((('angina pectoris'/exp OR 'aortic valve stenosis'/exp OR 'heart arrhythmia'/exp OR 'atherosclerosis'/exp OR 'atrial fibrillation'/exp OR 'cardiomyopathy'/exp OR 'cardiovascular disease'/exp OR 'coronary artery disease'/exp OR 'embolism'/exp OR 'heart failure'/exp OR 'heart infarction'/exp OR 'heart muscle ischemia'/exp OR 'myocarditis'/exp OR 'peripheral vascular disease'/exp OR 'cerebrovascular accident'/exp OR 'thromboembolism'/exp OR 'venous thromboembolism'/exp OR 'heart disease'/exp OR 'aortic stenosis'/exp OR 'atherogenesis'/exp OR 'ambulatory electrocardiographic monitor'/exp OR 'carditis'/exp OR 'coronary artery atherosclerosis'/exp OR 'ischemic heart disease'/exp OR 'major adverse cardiac event'/exp OR 'myocardial disease'/exp OR 'paroxysmal atrial fibrillation'/exp OR 'transient ischemic attack'/exp) OR ('acute stroke*':ab,ti OR 'angina':ab,ti OR 'angor pectoris':ab,ti OR 'aortic stenosis*':ab,ti OR 'aortic valve stenosis*':ab,ti OR 'apoplexy':ab,ti OR 'arrhythmia':ab,ti OR 'arrythmia*':ab,ti OR 'atherogenesis':ab,ti OR 'atherosclerosis*':ab,ti OR 'atrial fibrillation*':ab,ti OR 'auricular fibrillation*':ab,ti OR 'brain vascular accident*':ab,ti OR 'cardiac arrhythmia*':ab,ti OR 'cardiac decompensation*':ab,ti OR 'cardiac disease*':ab,ti OR 'cardiac dysrhythmia*':ab,ti OR 'cardiac event*':ab,ti OR 'cardiac failure':ab,ti OR 'cardiomyopath*':ab,ti OR 'cardiovascular disease*':ab,ti OR 'cardiovascular event*':ab,ti OR 'cardiovascular outcome*':ab,ti OR 'cardiovascular stroke*':ab,ti OR 'carditis':ab,ti OR 'cerebral stroke*':ab,ti OR 'cerebrovascular accident*':ab,ti OR 'cerebrovascular apoplexy':ab,ti OR 'cerebrovascular stroke*':ab,ti OR 'coronary arteriosclerosis*':ab,ti OR 'coronary artery disease*':ab,ti OR 'coronary atherosclerosis*':ab,ti OR 'embolism*':ab,ti OR 'embolus':ab,ti OR 'heart arrhythmia*':ab,ti OR 'heart attack*':ab,ti OR 'heart decompensation*':ab,ti OR 'heart disease*':ab,ti OR 'heart event*':ab,ti OR 'heart failure':ab,ti OR 'heart muscle ischemi*':ab,ti OR 'ischaemic heart disease*':ab,ti OR 'ischemic heart disease*':ab,ti OR 'major adverse cardiac event*':ab,ti OR 'myocardial decompensation*':ab,ti OR 'myocardial disease*':ab,ti OR 'myocardial failure':ab,ti OR 'myocardial infarct*':ab,ti OR 'myocardial ischaemi*':ab,ti OR 'myocardial ischemi*':ab,ti OR 'myocardiopath*':ab,ti OR 'myocarditides':ab,ti OR 'myocarditis':ab,ti OR</p>


	<p>'paroxysmal atrial':ab,ti OR 'peripheral angiopath*':ab,ti OR 'peripheral vascular disease*':ab,ti OR 'stenocardia*':ab,ti OR 'stroke*':ab,ti OR 'thromboembolism*':ab,ti OR 'transient ischaemi*':ab,ti OR 'transient ischemi*':ab,ti))) NOT ('animal'/de NOT ('animal'/de AND 'human'/exp))</p>
Cochrane	<p>((MeSH descriptor: [Breast Neoplasms] explode all trees) OR ((Breast neoplasm*):ti,ab,kw OR (Breast tumor*):ti,ab,kw OR (Breast carcinoma*):ti,ab,kw OR (Human mammary neoplasm*):ti,ab,kw OR (Breast cancer*):ti,ab,kw OR (Mammary neoplasm*):ti,ab,kw OR (Mammary cancer*):ti,ab,kw OR (Mammary carcinoma*):ti,ab,kw OR (Mammary tumor*):ti,ab,kw OR (Breast malignant neoplasm*):ti,ab,kw OR (Breast malignant tumor*):ti,ab,kw OR (Breast malignant cancer*):ti,ab,kw OR (Breast malignant carcinoma*):ti,ab,kw)) AND ((MeSH descriptor: [Tamoxifen] explode all trees OR MeSH descriptor: [Toremifene] explode all trees OR MeSH descriptor: [Letrozole] explode all trees OR MeSH descriptor: [Anastrozole] explode all trees OR MeSH descriptor: [Antineoplastic Agents, Hormonal] explode all trees OR MeSH descriptor: [Selective Estrogen Receptor Modulators] explode all trees OR MeSH descriptor: [Aromatase Inhibitors] explode all trees) OR ((Tamoxifen*):ti,ab,kw OR (ICI-47699):ti,ab,kw OR (ICI47699):ti,ab,kw OR (Nolvadex):ti,ab,kw OR (Novaldex):ti,ab,kw OR (Tamoxifen citrate):ti,ab,kw OR (Tomaxithen):ti,ab,kw OR (Zitazonium):ti,ab,kw OR (ICI-46474):ti,ab,kw OR (ICI46474):ti,ab,kw OR (ICI-46,474):ti,ab,kw OR (ICI46,474):ti,ab,kw OR (Soltamox):ti,ab,kw OR (Crisafeno):ti,ab,kw OR (Toremifene):ti,ab,kw OR (Fareston):ti,ab,kw OR (FC-1157a):ti,ab,kw OR (FC1157a):ti,ab,kw OR (CGS-20267):ti,ab,kw OR (CGS20267):ti,ab,kw OR (Femara):ti,ab,kw OR (Letrozole):ti,ab,kw OR (Anastrozole):ti,ab,kw OR (Anastrozole):ti,ab,kw OR (ICI D1033):ti,ab,kw OR (ZD-1033):ti,ab,kw OR (ZD1033):ti,ab,kw OR (Arimidex):ti,ab,kw OR (Exemestane):ti,ab,kw OR (Examestane):ti,ab,kw OR (FCE 24304):ti,ab,kw OR (FCE24304):ti,ab,kw OR (Aromasin):ti,ab,kw OR (Hormonal antineoplast*):ti,ab,kw OR (Antineoplastic hormon*):ti,ab,kw OR (SERM*):ti,ab,kw OR (Selective estrogen receptor modulator*):ti,ab,kw OR (Aromatase inhibitor*):ti,ab,kw)) AND ((MeSH descriptor: [Angina Pectoris] explode all trees OR MeSH descriptor: [Aortic Valve Stenosis] explode all trees OR MeSH descriptor: [Arrhythmias, Cardiac] explode all trees OR MeSH descriptor: [Atherosclerosis] explode all trees OR MeSH descriptor: [Atrial Fibrillation] explode all trees OR MeSH descriptor: [Cardiomyopathies] explode all trees OR MeSH descriptor: [Cardiovascular Diseases] explode all trees OR MeSH descriptor: [Coronary Artery Disease] explode all trees OR MeSH descriptor: [Embolism] explode all trees OR MeSH descriptor: [Heart Failure] explode all trees OR MeSH descriptor: [Myocardial Infarction] explode all trees OR MeSH descriptor: [Myocardial Ischemia] explode all trees OR MeSH descriptor: [Myocarditis] explode all trees OR MeSH descriptor: [Peripheral Vascular Diseases] explode all trees OR MeSH descriptor: [Stroke] explode all trees OR MeSH descriptor: [Thromboembolism] explode all trees OR MeSH descriptor: [Venous Thromboembolism] explode all trees OR MeSH descriptor: [Heart Diseases] explode all trees) OR ((Acute stroke*):ti,ab,kw OR (Angina):ti,ab,kw OR (Angor pectoris):ti,ab,kw OR (Aortic stenosis*):ti,ab,kw OR (Aortic valve stenosis*):ti,ab,kw OR (Apoplexy):ti,ab,kw OR (Arrhythmia):ti,ab,kw OR (Arrhythmia):ti,ab,kw OR (Atherogenesis):ti,ab,kw OR (Atherosclerosis*):ti,ab,kw OR (Atrial fibrillation*):ti,ab,kw OR (Auricular fibrillation*):ti,ab,kw OR (Brain vascular accident*):ti,ab,kw OR (Cardiac arrhythmia*):ti,ab,kw OR (Cardiac decompensation*):ti,ab,kw OR (Cardiac disease*):ti,ab,kw OR (Cardiac dysrhythmia*):ti,ab,kw OR (Cardiac event*):ti,ab,kw OR (Cardiac failure):ti,ab,kw OR (Cardiomyopath*):ti,ab,kw OR (Cardiovascular disease*):ti,ab,kw OR (Cardiovascular event*):ti,ab,kw OR (Cardiovascular outcome*):ti,ab,kw OR (Cardiovascular stroke*):ti,ab,kw OR (Carditis):ti,ab,kw OR (Cerebral stroke*):ti,ab,kw OR (Cerebrovascular accident*):ti,ab,kw OR (Cerebrovascular apoplexy):ti,ab,kw OR (Cerebrovascular stroke*):ti,ab,kw OR (Coronary arteriosclerosis*):ti,ab,kw OR (Coronary artery disease*):ti,ab,kw OR (Coronary atherosclerosis*):ti,ab,kw OR (Embolism*):ti,ab,kw OR (Embolus):ti,ab,kw OR (Heart attack*):ti,ab,kw OR (Heart decompensation*):ti,ab,kw OR (Heart disease*):ti,ab,kw OR (Heart event*):ti,ab,kw OR (Heart failure):ti,ab,kw OR (Ischaemic heart disease*):ti,ab,kw OR (Ischemic heart disease*):ti,ab,kw OR (Major adverse cardiac event*):ti,ab,kw OR (Myocardial decompensation*):ti,ab,kw OR (Myocardial disease*):ti,ab,kw OR (Myocardial failure):ti,ab,kw OR (Myocardial infarct*):ti,ab,kw OR (Myocardial ischaemi*):ti,ab,kw OR (Myocardial ischemi*):ti,ab,kw OR (Myocardiopath*):ti,ab,kw OR (Myocarditides):ti,ab,kw OR (Myocarditis):ti,ab,kw OR (Paroxysmal</p>

	atrial):ti,ab,kw OR (Peripheral angiopath*):ti,ab,kw OR (Peripheral vascular disease*):ti,ab,kw OR (Stenocardia*):ti,ab,kw OR (Stroke*):ti,ab,kw OR (Thromboembolism*):ti,ab,kw OR (Transient ischaemi*):ti,ab,kw OR (Transient ischemi*):ti,ab,kw)) NOT (MeSH descriptor: [Animals] this term only NOT (MeSH descriptor: [Animals] this term only AND MeSH descriptor: [Humans] this term only))
Web of Science	(TI=("Breast neoplasm*" OR "Breast tumor*" OR "Breast carcinoma*" OR "Human mammary neoplasm*" OR "Breast cancer*" OR "Mammary neoplasm*" OR "Mammary cancer*" OR "Mammary carcinoma*" OR "Mammary tumor*" OR "Breast malignant neoplasm*" OR "Breast malignant tumor*" OR "Breast malignant cancer*" OR "Breast malignant carcinoma*")) OR AB=("Breast neoplasm*" OR "Breast tumor*" OR "Breast carcinoma*" OR "Human mammary neoplasm*" OR "Breast cancer*" OR "Mammary neoplasm*" OR "Mammary cancer*" OR "Mammary carcinoma*" OR "Mammary tumor*" OR "Breast malignant neoplasm*" OR "Breast malignant tumor*" OR "Breast malignant cancer*" OR "Breast malignant carcinoma*") AND (TI=("Tamoxifen*" OR "ICI-47699" OR "ICI47699" OR "Nolvadex" OR "Novaldex" OR "Tamoxifen citrate" OR "Tomaxithen" OR "Zitazonium" OR "ICI-46474" OR "ICI46474" OR "ICI-46,474" OR "ICI46,474" OR "Soltamox" OR "Crisafeno" OR "Toremifene" OR "Fareston" OR "FC-1157a" OR "FC1157a" OR "CGS-20267" OR "CGS20267" OR "Femara" OR "Letrozole" OR "Anastrozole" OR "Anastrozole" OR "ICI D1033" OR "ZD-1033" OR "ZD1033" OR "Arimidex" OR "Exemestane" OR "Examestane" OR "FCE 24304" OR "FCE24304" OR "Aromasin" OR "Hormonal antineoplast*" OR "Antineoplastic hormon*" OR "SERM*" OR "Selective estrogen receptor modulator*" OR "Aromatase inhibitor*")) OR AB=("Tamoxifen*" OR "ICI-47699" OR "ICI47699" OR "Nolvadex" OR "Novaldex" OR "Tamoxifen citrate" OR "Tomaxithen" OR "Zitazonium" OR "ICI-46474" OR "ICI46474" OR "ICI-46,474" OR "ICI46,474" OR "Soltamox" OR "Crisafeno" OR "Toremifene" OR "Fareston" OR "FC-1157a" OR "FC1157a" OR "CGS-20267" OR "CGS20267" OR "Femara" OR "Letrozole" OR "Anastrozole" OR "Anastrozole" OR "ICI D1033" OR "ZD-1033" OR "ZD1033" OR "Arimidex" OR "Exemestane" OR "Examestane" OR "FCE 24304" OR "FCE24304" OR "Aromasin" OR "Hormonal antineoplast*" OR "Antineoplastic hormon*" OR "SERM*" OR "Selective estrogen receptor modulator*" OR "Aromatase inhibitor*") AND (TI=("Acute stroke*" OR "Angina" OR "Angor pectoris" OR "Aortic stenosis*" OR "Aortic valve stenosis*" OR "Apoplexy" OR "Arrhythmia" OR "Arrhythmia" OR "Atherogenesis" OR "Atherosclerosis*" OR "Atrial fibrillation*" OR "Auricular fibrillation*" OR "Brain vascular accident*" OR "Cardiac arrhythmia*" OR "Cardiac decompensation*" OR "Cardiac disease*" OR "Cardiac dysrhythmia*" OR "Cardiac event*" OR "Cardiac failure" OR "Cardiomyopathy*" OR "Cardiovascular disease*" OR "Cardiovascular event*" OR "Cardiovascular outcome*" OR "Cardiovascular stroke*" OR "Carditis" OR "Cerebral stroke*" OR "Cerebrovascular accident*" OR "Cerebrovascular apoplexy" OR "Cerebrovascular stroke*" OR "Coronary arteriosclerosis*" OR "Coronary artery disease*" OR "Coronary atherosclerosis*" OR "Embolism*" OR "Embolus" OR "Heart attack*" OR "Heart decompensation*" OR "Heart disease*" OR "Heart event*" OR "Heart failure" OR "Ischaemic heart disease*" OR "Ischemic heart disease*" OR "Major adverse cardiac event*" OR "Myocardial decompensation*" OR "Myocardial disease*" OR "Myocardial failure" OR "Myocardial infarct*" OR "Myocardial ischaemia*" OR "Myocardial ischemia*" OR "Myocardiopathy*" OR "Myocarditis" OR "Myocarditis" OR "Paroxysmal atrial" OR "Peripheral angiopathy*" OR "Peripheral vascular disease*" OR "Stenocardia*" OR "Stroke*" OR "Thromboembolism*" OR "Transient ischaemia*" OR "Transient ischemia*")) OR AB=("Acute stroke*" OR "Angina" OR "Angor pectoris" OR "Aortic stenosis*" OR "Aortic valve stenosis*" OR "Apoplexy" OR "Arrhythmia" OR "Arrhythmia" OR "Atherogenesis" OR "Atherosclerosis*" OR "Atrial fibrillation*" OR "Auricular fibrillation*" OR "Brain vascular accident*" OR "Cardiac arrhythmia*" OR "Cardiac decompensation*" OR "Cardiac disease*" OR "Cardiac dysrhythmia*" OR "Cardiac event*" OR "Cardiac failure" OR "Cardiomyopathy*" OR "Cardiovascular disease*" OR "Cardiovascular event*" OR "Cardiovascular outcome*" OR "Cardiovascular stroke*" OR "Carditis" OR "Cerebral stroke*" OR "Cerebrovascular accident*" OR "Cerebrovascular apoplexy" OR "Cerebrovascular stroke*" OR "Coronary arteriosclerosis*" OR "Coronary artery disease*" OR "Coronary atherosclerosis*" OR "Embolism*" OR "Embolus" OR "Heart attack*" OR "Heart decompensation*" OR "Heart disease*" OR "Heart event*" OR "Heart failure" OR "Ischaemic heart disease*" OR "Ischemic heart disease*" OR "Major adverse cardiac event*" OR "Myocardial decompensation*" OR "Myocardial disease*" OR "Myocardial failure" OR "Myocardial infarct*" OR "Myocardial ischaemia*" OR

	<p>"Myocardial ischemi*" OR "Myocardiopath*" OR "Myocarditides" OR "Myocarditis" OR "Paroxysmal atrial" OR "Peripheral angiopath*" OR "Peripheral vascular disease*" OR "Stenocardia*" OR "Stroke*" OR "Thromboembolism*" OR "Transient ischaemi*" OR "Transient ischemi*")</p>
KoreaMed	<p>((("Breast neoplasms"[MH]) OR (((((((((((("Breast neoplasm"[TIAB])) OR ("Breast tumor"[TIAB])) OR ("Breast carcinoma"[TIAB])) OR ("Human mammary neoplasm"[TIAB])) OR ("Breast cancer"[TIAB])) OR ("Mammary neoplasm"[TIAB])) OR ("Mammary cancer"[TIAB])) OR ("Mammary carcinoma"[TIAB])) OR ("Mammary tumor"[TIAB])) OR ("Breast malignant neoplasm"[TIAB])) OR ("Breast malignant tumor"[TIAB])) OR ("Breast malignant cancer"[TIAB])) OR ("Breast malignant carcinoma"[TIAB])) AND (((((((("Tamoxifen"[MH])) OR ("Toremifene"[MH])) OR ("Letrozole"[MH])) OR ("Anastrozole"[MH])) OR ("Antineoplastic agents, hormonal"[MH])) OR ("Selective estrogen receptor modulators"[MH])) OR ("Aromatase inhibitors"[MH])) OR (((((((((((((((("Tamoxifen"[TIAB])) OR ("ICI-47699"[TIAB])) OR ("ICI47699"[TIAB])) OR ("Nolvadex"[TIAB])) OR ("Novaldex"[TIAB])) OR ("Tamoxifen citrate"[TIAB])) OR ("Tomaxithen"[TIAB])) OR ("Zitazonium"[TIAB])) OR ("ICI-46474"[TIAB])) OR ("ICI46474"[TIAB])) OR ("ICI-46,474"[TIAB])) OR ("ICI46,474"[TIAB])) OR ("Soltamox"[TIAB])) OR ("Crisafeno"[TIAB])) OR ("Toremifene"[TIAB])) AND ("Fareston"[TIAB])) AND ("FC-1157a"[TIAB])) OR ("FC1157a"[TIAB])) OR ("CGS-20267"[TIAB])) OR ("CGS20267"[TIAB])) OR ("Femara"[TIAB])) OR ("Letrozole"[TIAB])) OR ("Anastrozole"[TIAB])) OR ("Anastrozole"[TIAB])) OR ("ICI D1033"[TIAB])) OR ("ZD-1033"[TIAB])) OR ("ZD1033"[TIAB])) OR ("Arimidex"[TIAB])) OR ("Exemestane"[TIAB])) OR ("Examestane"[TIAB])) OR ("FCE 24304"[TIAB])) OR ("FCE24304"[TIAB])) OR ("Aromasin"[TIAB])) OR ("Hormonal antineoplast*" [TIAB])) OR ("Antineoplastic hormon*" [TIAB])) OR ("SERM*" [TIAB])) OR ("Selective estrogen receptor modulator*" [TIAB])) OR ("Aromatase inhibitor*" [TIAB])) AND (((((((((((((((("Angina pectoris"[MH])) OR ("Aortic valve stenosis"[MH])) OR ("Arrhythmias, cardiac"[MH])) OR ("Atherosclerosis"[MH])) OR ("Atrial fibrillation"[MH])) OR ("Cardiomyopathies"[MH])) OR ("Cardiovascular diseases"[MH])) OR ("Coronary artery disease"[MH])) OR ("Embolism"[MH])) OR ("Heart failure"[MH])) OR ("Myocardial infarction"[MH])) OR ("Myocardial ischemia"[MH])) OR ("Myocarditis"[MH])) OR ("Peripheral vascular diseases"[MH])) OR ("Stroke"[MH])) OR ("Thromboembolism"[MH])) OR ("Venous thromboembolism"[MH])) OR ("Heart diseases"[MH])) OR (((((((((((((((((((("Acute stroke*" [TIAB])) OR ("Angina"[TIAB])) OR ("Angor pectoris"[TIAB])) OR ("Aortic stenosis*" [TIAB])) OR ("Aortic valve stenosis*" [TIAB])) OR ("Apoplexy"[TIAB])) OR ("Arrhythmia"[TIAB])) OR ("Arrythmia"[TIAB])) OR ("Atherogenesis"[TIAB])) OR ("Atherosclerosis*" [TIAB])) OR ("Atrial fibrillation*" [TIAB])) OR ("Auricular fibrillation*" [TIAB])) OR ("Brain vascular accident*" [TIAB])) OR ("Cardiac arrhythmia*" [TIAB])) OR ("Cardiac decompensation*" [TIAB])) OR ("Cardiac disease*" [TIAB])) OR ("Cardiac dysrhythmia*" [TIAB])) OR ("Cardiac event*" [TIAB])) OR ("Cardiac failure"[TIAB])) OR ("Cardiomyopathy*" [TIAB])) OR ("Cardiovascular disease*" [TIAB])) OR ("Cardiovascular event*" [TIAB])) OR ("Cardiovascular outcome*" [TIAB])) OR ("Cardiovascular stroke*" [TIAB])) OR ("Carditis"[TIAB])) OR ("Cerebral stroke*" [TIAB])) OR ("Cerebrovascular accident*" [TIAB])) OR ("Cerebrovascular apoplexy"[TIAB])) OR ("Cerebrovascular stroke*" [TIAB])) OR ("Coronary arteriosclerosis*" [TIAB])) OR ("Coronary artery disease*" [TIAB])) OR ("Coronary atherosclerosis*" [TIAB])) OR ("Embolism*" [TIAB])) OR ("Embolus"[TIAB])) OR ("Heart attack*" [TIAB])) OR ("Heart decompensation*" [TIAB])) OR ("Heart disease*" [TIAB])) OR ("Heart event*" [TIAB])) OR ("Heart failure"[TIAB])) OR ("Ischaemic heart disease*" [TIAB])) OR ("Ischemic heart disease*" [TIAB])) OR ("Major adverse cardiac event*" [TIAB])) OR ("Myocardial decompensation*" [TIAB])) OR ("Myocardial disease*" [TIAB])) OR ("Myocardial failure"[TIAB])) OR ("Myocardial infarct*" [TIAB])) OR ("Myocardial ischaemi*" [TIAB])) OR ("Myocardial ischemi*" [TIAB])) OR ("Myocardiopath*" [TIAB])) OR ("Myocarditides"[TIAB])) OR ("Myocarditis"[TIAB])) OR ("Paroxysmal atrial"[TIAB])) OR ("Peripheral angiopath*" [TIAB])) OR ("Peripheral vascular disease*" [TIAB])) OR ("Stenocardia*" [TIAB])) OR ("Stroke*" [TIAB])) OR ("Thromboembolism*" [TIAB])) OR ("Transient ischaemi*" [TIAB])) OR ("Transient ischemi*" [TIAB])) Limitation Human</p>


2. Risk of bias

1) Randomized controlled study



	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Atalay 2004	+	+	+	+	+	+	+
Lonning 2005	?	+	+	+	+	+	+
Markopoulos 2005	?	+	+	+	+	+	+
Markopoulos 2009	+	?	+	+	+	+	+
Rabaglio 2021	+	+	+	+	+	+	+
Sawada 2005	?	?	+	+	+	+	+
Thurlimann 2005	+	+	+	+	+	+	+


2) Non-randomized controlled study





	Selection of participants	Confounding variables	Measurement of exposure	Blinding of outcome assessments	Incomplete outcome data	Selective outcome reporting
Abdel-Qadir 2016	+	+	+	+	+	+
Chang 2022	-	+	+	+	+	+
Choi 2020	+	?	+	+	+	+
Faiz 2021	+	+	+	+	+	+
Franchi 2021	-	?	+	+	+	+
Haque 2016	-	+	+	+	+	+
Kamaraju 2019	-	+	+	+	+	+
Khosrow-Khavar 2020	+	+	+	+	+	+
Khosrow-Khavar 2020_2	-	+	+	+	+	+
Ligibel 2012	+	-	+	+	+	+
Matthews 2021	-	+	+	+	+	+
Pineda-Moncusi 2020	+	+	+	+	+	+
Santa-Maria 2016	+	+	+	+	+	+
Seruga 2014	?	+	+	+	+	+
Sund 2021	+	-	+	+	+	+
Tian 2018	+	-	+	+	+	+
Wojtacki 2001	+	-	+	+	+	+
Xu 2019	?	+	+	+	+	+

II. Supplementary Figures



Supplementary Figure S1. Forest plots and funnel plots of Table 2





Heart
failure




All stroke




Ischemic
stroke






Supplementary Figure S2. Forest plots and funnel plots of Table 3



Heart
failure

Study	Experimental Events	Experimental Total	Control Events	Control Total	Odds Ratio	OR	95%-CI	Weight (fixed)	Weight (random)
Matthews 2021	1368	15074	233	2286		0.88	[0.76; 1.02]	29.6%	14.1%
Rabaglio 2021	16	1535	17	1541		0.94	[0.48; 1.88]	1.3%	10.6%
Khosrow-Khavar 2020 (1)	13	1962	14	3874		1.84	[0.86; 3.92]	0.8%	10.0%
Franchi 2021	266	7881	243	7881		1.10	[0.92; 1.31]	18.9%	14.0%
Khosrow-Khavar 2020 (2)	83	8139	33	9783		3.04	[2.03; 4.56]	2.4%	12.7%
Chang 2022	492	11728	432	16730		1.65	[1.45; 1.88]	27.4%	14.1%
Thurlimann 2005	31	3975	14	3988		2.23	[1.19; 4.20]	1.1%	11.0%
Haque 2016	69	3807	248	4207		0.29	[0.22; 0.39]	18.6%	13.6%
Fixed effect model		54101		50290		1.10	[1.02; 1.19]	100.0%	--
Random effects model						1.20	[0.78; 1.86]	--	100.0%



Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.3465$, $p < 0.01$



All
stroke

Study	Experimental Events	Experimental Total	Control Events	Control Total	Odds Ratio	OR	95%-CI	Weight (fixed)	Weight (random)
Matthews 2021	1126	15074	190	2286		0.89	[0.76; 1.05]	81.7%	59.5%
Choi 2020	161	19584	47	7081		1.24	[0.90; 1.72]	18.3%	40.5%
Fixed effect model		34658		9367		0.95	[0.83; 1.10]	100.0%	--
Random effects model						1.02	[0.74; 1.40]	--	100.0%


Heterogeneity: $I^2 = 69\%$, $\tau^2 = 0.0378$, $p = 0.07$




Ischemic
stroke

Study	Experimental Events	Experimental Total	Control Events	Control Total	Odds Ratio	OR	95%-CI	Weight (fixed)	Weight (random)
Khosrow-Khavar 2020 (1)	19	1962	22	3874		1.71	[0.92; 3.17]	1.8%	10.7%
Choi 2020	529	19584	183	7081		1.05	[0.88; 1.24]	32.3%	23.7%
Franchi 2021	182	7881	163	7881		1.12	[0.90; 1.39]	19.7%	22.4%
Khosrow-Khavar 2020 (2)	86	8139	59	9783		1.76	[1.26; 2.45]	6.6%	18.5%
Chang 2022	477	11728	406	16730		1.70	[1.49; 1.95]	39.7%	24.7%
Fixed effect model		49294		45349		1.38	[1.26; 1.51]	100.0%	--
Random effects model						1.39	[1.07; 1.81]	--	100.0%

Heterogeneity: $I^2 = 85\%$, $\tau^2 = 0.0674$, $p < 0.01$













Supplementary Figure S3. Forest plots and funnel plots of Table 4

	Forest plots	Funnel Plots																																																																
Comparison with baseline																																																																		
HDL 6-mo	<table><thead><tr><th>Study</th><th>TE</th><th>seTE</th><th>Mean Difference</th><th>MD</th><th>95%-CI</th><th>Weight (fixed)</th><th>Weight (random)</th></tr></thead><tbody><tr><td>Atalay 2004</td><td>-2.71</td><td>2.4540</td><td></td><td>-2.71</td><td>[-7.52; 2.10]</td><td>0.2%</td><td>9.6%</td></tr><tr><td>Markopoulos 2009</td><td>-4.30</td><td>0.1239</td><td></td><td>-4.30</td><td>[-4.54; -4.06]</td><td>94.9%</td><td>31.6%</td></tr><tr><td>Tian 2018</td><td>1.93</td><td>2.8614</td><td></td><td>1.93</td><td>[-3.68; 7.54]</td><td>0.2%</td><td>7.7%</td></tr><tr><td>Tian 2018</td><td>-1.93</td><td>0.7493</td><td></td><td>-1.93</td><td>[-3.40; -0.46]</td><td>2.6%</td><td>26.2%</td></tr><tr><td>Markopoulos 2005</td><td>-2.00</td><td>0.8454</td><td></td><td>-2.00</td><td>[-3.66; -0.34]</td><td>2.0%</td><td>24.9%</td></tr><tr><td colspan="4">Fixed effect model</td><td>-4.18 [-4.41; -3.94]</td><td>100.0%</td><td>--</td><td>--</td></tr><tr><td colspan="4">Random effects model</td><td>-2.47 [-4.26; -0.69]</td><td>--</td><td>--</td><td>100.0%</td></tr></tbody></table> <p>Heterogeneity: $I^2 = 81\%$, $\tau^2 = 2.6208$, $p < 0.01$</p>	Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)	Atalay 2004	-2.71	2.4540		-2.71	[-7.52; 2.10]	0.2%	9.6%	Markopoulos 2009	-4.30	0.1239		-4.30	[-4.54; -4.06]	94.9%	31.6%	Tian 2018	1.93	2.8614		1.93	[-3.68; 7.54]	0.2%	7.7%	Tian 2018	-1.93	0.7493		-1.93	[-3.40; -0.46]	2.6%	26.2%	Markopoulos 2005	-2.00	0.8454		-2.00	[-3.66; -0.34]	2.0%	24.9%	Fixed effect model				-4.18 [-4.41; -3.94]	100.0%	--	--	Random effects model				-2.47 [-4.26; -0.69]	--	--	100.0%	
Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)																																																											
Atalay 2004	-2.71	2.4540		-2.71	[-7.52; 2.10]	0.2%	9.6%																																																											
Markopoulos 2009	-4.30	0.1239		-4.30	[-4.54; -4.06]	94.9%	31.6%																																																											
Tian 2018	1.93	2.8614		1.93	[-3.68; 7.54]	0.2%	7.7%																																																											
Tian 2018	-1.93	0.7493		-1.93	[-3.40; -0.46]	2.6%	26.2%																																																											
Markopoulos 2005	-2.00	0.8454		-2.00	[-3.66; -0.34]	2.0%	24.9%																																																											
Fixed effect model				-4.18 [-4.41; -3.94]	100.0%	--	--																																																											
Random effects model				-2.47 [-4.26; -0.69]	--	--	100.0%																																																											
HDL 12-mo	<table><thead><tr><th>Study</th><th>TE</th><th>seTE</th><th>Mean Difference</th><th>MD</th><th>95%-CI</th><th>Weight (fixed)</th><th>Weight (random)</th></tr></thead><tbody><tr><td>Markopoulos 2009</td><td>-3.00</td><td>0.1583</td><td></td><td>-3.00</td><td>[-3.31; -2.69]</td><td>96.2%</td><td>30.7%</td></tr><tr><td>Tian 2018</td><td>5.03</td><td>1.9528</td><td></td><td>5.03</td><td>[1.20; 8.86]</td><td>0.6%</td><td>24.8%</td></tr><tr><td>Tian 2018</td><td>2.32</td><td>0.9007</td><td></td><td>2.32</td><td>[0.55; 4.09]</td><td>3.0%</td><td>29.3%</td></tr><tr><td>Markopoulos 2005</td><td>1.00</td><td>4.0505</td><td></td><td>1.00</td><td>[-6.94; 8.94]</td><td>0.1%</td><td>15.1%</td></tr><tr><td colspan="4">Fixed effect model</td><td>-2.79 [-3.09; -2.48]</td><td>100.0%</td><td>--</td><td>--</td></tr><tr><td colspan="4">Random effects model</td><td>1.16 [-3.18; 5.49]</td><td>--</td><td>--</td><td>100.0%</td></tr></tbody></table> <p>Heterogeneity: $I^2 = 94\%$, $\tau^2 = 15.8737$, $p < 0.01$</p>	Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)	Markopoulos 2009	-3.00	0.1583		-3.00	[-3.31; -2.69]	96.2%	30.7%	Tian 2018	5.03	1.9528		5.03	[1.20; 8.86]	0.6%	24.8%	Tian 2018	2.32	0.9007		2.32	[0.55; 4.09]	3.0%	29.3%	Markopoulos 2005	1.00	4.0505		1.00	[-6.94; 8.94]	0.1%	15.1%	Fixed effect model				-2.79 [-3.09; -2.48]	100.0%	--	--	Random effects model				1.16 [-3.18; 5.49]	--	--	100.0%									
Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)																																																											
Markopoulos 2009	-3.00	0.1583		-3.00	[-3.31; -2.69]	96.2%	30.7%																																																											
Tian 2018	5.03	1.9528		5.03	[1.20; 8.86]	0.6%	24.8%																																																											
Tian 2018	2.32	0.9007		2.32	[0.55; 4.09]	3.0%	29.3%																																																											
Markopoulos 2005	1.00	4.0505		1.00	[-6.94; 8.94]	0.1%	15.1%																																																											
Fixed effect model				-2.79 [-3.09; -2.48]	100.0%	--	--																																																											
Random effects model				1.16 [-3.18; 5.49]	--	--	100.0%																																																											
LDL 6-mo	<table><thead><tr><th>Study</th><th>TE</th><th>seTE</th><th>Mean Difference</th><th>MD</th><th>95%-CI</th><th>Weight (fixed)</th><th>Weight (random)</th></tr></thead><tbody><tr><td>Markopoulos 2009</td><td>24.30</td><td>0.4337</td><td></td><td>24.30</td><td>[23.45; 25.15]</td><td>98.6%</td><td>26.6%</td></tr><tr><td>Tian 2018</td><td>6.57</td><td>9.7407</td><td></td><td>6.57</td><td>[-12.52; 25.66]</td><td>0.2%</td><td>17.3%</td></tr><tr><td>Tian 2018</td><td>-4.25</td><td>6.3011</td><td></td><td>-4.25</td><td>[-16.60; 8.10]</td><td>0.5%</td><td>21.7%</td></tr><tr><td>Tian 2018</td><td>10.25</td><td>15.1967</td><td></td><td>10.25</td><td>[-19.53; 40.03]</td><td>0.1%</td><td>11.5%</td></tr><tr><td>Markopoulos 2005</td><td>11.50</td><td>5.4243</td><td></td><td>11.50</td><td>[0.87; 22.13]</td><td>0.6%</td><td>22.8%</td></tr><tr><td colspan="4">Fixed effect model</td><td>24.04 [23.20; 24.88]</td><td>100.0%</td><td>--</td><td>--</td></tr><tr><td colspan="4">Random effects model</td><td>10.48 [-2.95; 23.92]</td><td>--</td><td>--</td><td>100.0%</td></tr></tbody></table> <p>Heterogeneity: $I^2 = 87\%$, $\tau^2 = 176.5458$, $p < 0.01$</p>	Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)	Markopoulos 2009	24.30	0.4337		24.30	[23.45; 25.15]	98.6%	26.6%	Tian 2018	6.57	9.7407		6.57	[-12.52; 25.66]	0.2%	17.3%	Tian 2018	-4.25	6.3011		-4.25	[-16.60; 8.10]	0.5%	21.7%	Tian 2018	10.25	15.1967		10.25	[-19.53; 40.03]	0.1%	11.5%	Markopoulos 2005	11.50	5.4243		11.50	[0.87; 22.13]	0.6%	22.8%	Fixed effect model				24.04 [23.20; 24.88]	100.0%	--	--	Random effects model				10.48 [-2.95; 23.92]	--	--	100.0%	
Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)																																																											
Markopoulos 2009	24.30	0.4337		24.30	[23.45; 25.15]	98.6%	26.6%																																																											
Tian 2018	6.57	9.7407		6.57	[-12.52; 25.66]	0.2%	17.3%																																																											
Tian 2018	-4.25	6.3011		-4.25	[-16.60; 8.10]	0.5%	21.7%																																																											
Tian 2018	10.25	15.1967		10.25	[-19.53; 40.03]	0.1%	11.5%																																																											
Markopoulos 2005	11.50	5.4243		11.50	[0.87; 22.13]	0.6%	22.8%																																																											
Fixed effect model				24.04 [23.20; 24.88]	100.0%	--	--																																																											
Random effects model				10.48 [-2.95; 23.92]	--	--	100.0%																																																											



LDL 12-mo	<table><tr><th>Study</th><th>TE</th><th>seTE</th><th>Mean Difference</th><th>MD</th><th>95%-CI</th><th>Weight (fixed)</th><th>Weight (random)</th></tr><tr><td>Markopoulos 2009</td><td>20.10</td><td>0.4337</td><td></td><td>20.10</td><td>[19.25; 20.95]</td><td>98.3%</td><td>25.1%</td></tr><tr><td>Tian 2018</td><td>5.80</td><td>8.5991</td><td></td><td>5.80</td><td>[-11.05; 22.65]</td><td>0.3%</td><td>16.5%</td></tr><tr><td>Tian 2018</td><td>-3.48</td><td>5.1595</td><td></td><td>-3.48</td><td>[-13.59; 6.63]</td><td>0.7%</td><td>21.2%</td></tr><tr><td>Tian 2018</td><td>4.91</td><td>7.2796</td><td></td><td>4.91</td><td>[-9.36; 19.18]</td><td>0.3%</td><td>18.3%</td></tr><tr><td>Markopoulos 2005</td><td>10.00</td><td>6.8785</td><td></td><td>10.00</td><td>[-3.48; 23.48]</td><td>0.4%</td><td>18.9%</td></tr><tr><td>Fixed effect model</td><td></td><td></td><td></td><td>19.81</td><td>[18.97; 20.65]</td><td>100.0%</td><td>--</td></tr><tr><td>Random effects model</td><td></td><td></td><td></td><td>8.05</td><td>[-3.68; 19.79]</td><td>--</td><td>100.0%</td></tr></table> <p>Heterogeneity: $I^2 = 87\%$, $\tau^2 = 142.6174$, $p < 0.01$</p>	Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)	Markopoulos 2009	20.10	0.4337		20.10	[19.25; 20.95]	98.3%	25.1%	Tian 2018	5.80	8.5991		5.80	[-11.05; 22.65]	0.3%	16.5%	Tian 2018	-3.48	5.1595		-3.48	[-13.59; 6.63]	0.7%	21.2%	Tian 2018	4.91	7.2796		4.91	[-9.36; 19.18]	0.3%	18.3%	Markopoulos 2005	10.00	6.8785		10.00	[-3.48; 23.48]	0.4%	18.9%	Fixed effect model				19.81	[18.97; 20.65]	100.0%	--	Random effects model				8.05	[-3.68; 19.79]	--	100.0%									
Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)																																																																			
Markopoulos 2009	20.10	0.4337		20.10	[19.25; 20.95]	98.3%	25.1%																																																																			
Tian 2018	5.80	8.5991		5.80	[-11.05; 22.65]	0.3%	16.5%																																																																			
Tian 2018	-3.48	5.1595		-3.48	[-13.59; 6.63]	0.7%	21.2%																																																																			
Tian 2018	4.91	7.2796		4.91	[-9.36; 19.18]	0.3%	18.3%																																																																			
Markopoulos 2005	10.00	6.8785		10.00	[-3.48; 23.48]	0.4%	18.9%																																																																			
Fixed effect model				19.81	[18.97; 20.65]	100.0%	--																																																																			
Random effects model				8.05	[-3.68; 19.79]	--	100.0%																																																																			
TG 6-mo	<table><tr><th>Study</th><th>TE</th><th>seTE</th><th>Mean Difference</th><th>MD</th><th>95%-CI</th><th>Weight (fixed)</th><th>Weight (random)</th></tr><tr><td>Atalay 2004</td><td>-18.60</td><td>6.0189</td><td></td><td>-18.60</td><td>[-30.40; -6.80]</td><td>0.8%</td><td>22.3%</td></tr><tr><td>Markopoulos 2009</td><td>-24.10</td><td>0.5370</td><td></td><td>-24.10</td><td>[-25.15; -23.05]</td><td>98.5%</td><td>26.2%</td></tr><tr><td>Tian 2018</td><td>26.74</td><td>10.3811</td><td></td><td>26.74</td><td>[6.39; 47.09]</td><td>0.3%</td><td>17.2%</td></tr><tr><td>Tian 2018</td><td>-23.73</td><td>35.1822</td><td></td><td>-23.73</td><td>[-92.69; 45.23]</td><td>0.0%</td><td>3.7%</td></tr><tr><td>Tian 2018</td><td>-31.61</td><td>12.2718</td><td></td><td>-31.61</td><td>[-55.66; -7.56]</td><td>0.2%</td><td>15.2%</td></tr><tr><td>Markopoulos 2005</td><td>-13.50</td><td>12.0861</td><td></td><td>-13.50</td><td>[-37.19; 10.19]</td><td>0.2%</td><td>15.3%</td></tr><tr><td>Fixed effect model</td><td></td><td></td><td></td><td>-23.92</td><td>[-24.96; -22.87]</td><td>100.0%</td><td>--</td></tr><tr><td>Random effects model</td><td></td><td></td><td></td><td>-13.61</td><td>[-28.01; 0.79]</td><td>--</td><td>100.0%</td></tr></table> <p>Heterogeneity: $I^2 = 81\%$, $\tau^2 = 205.6795$, $p < 0.01$</p>	Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)	Atalay 2004	-18.60	6.0189		-18.60	[-30.40; -6.80]	0.8%	22.3%	Markopoulos 2009	-24.10	0.5370		-24.10	[-25.15; -23.05]	98.5%	26.2%	Tian 2018	26.74	10.3811		26.74	[6.39; 47.09]	0.3%	17.2%	Tian 2018	-23.73	35.1822		-23.73	[-92.69; 45.23]	0.0%	3.7%	Tian 2018	-31.61	12.2718		-31.61	[-55.66; -7.56]	0.2%	15.2%	Markopoulos 2005	-13.50	12.0861		-13.50	[-37.19; 10.19]	0.2%	15.3%	Fixed effect model				-23.92	[-24.96; -22.87]	100.0%	--	Random effects model				-13.61	[-28.01; 0.79]	--	100.0%	
Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)																																																																			
Atalay 2004	-18.60	6.0189		-18.60	[-30.40; -6.80]	0.8%	22.3%																																																																			
Markopoulos 2009	-24.10	0.5370		-24.10	[-25.15; -23.05]	98.5%	26.2%																																																																			
Tian 2018	26.74	10.3811		26.74	[6.39; 47.09]	0.3%	17.2%																																																																			
Tian 2018	-23.73	35.1822		-23.73	[-92.69; 45.23]	0.0%	3.7%																																																																			
Tian 2018	-31.61	12.2718		-31.61	[-55.66; -7.56]	0.2%	15.2%																																																																			
Markopoulos 2005	-13.50	12.0861		-13.50	[-37.19; 10.19]	0.2%	15.3%																																																																			
Fixed effect model				-23.92	[-24.96; -22.87]	100.0%	--																																																																			
Random effects model				-13.61	[-28.01; 0.79]	--	100.0%																																																																			
TG 12-mo	<table><tr><th>Study</th><th>TE</th><th>seTE</th><th>Mean Difference</th><th>MD</th><th>95%-CI</th><th>Weight (fixed)</th><th>Weight (random)</th></tr><tr><td>Markopoulos 2009</td><td>-32.20</td><td>0.5232</td><td></td><td>-32.20</td><td>[-33.23; -31.17]</td><td>99.4%</td><td>43.6%</td></tr><tr><td>Tian 2018</td><td>-5.05</td><td>7.4871</td><td></td><td>-5.05</td><td>[-19.72; 9.62]</td><td>0.5%</td><td>35.5%</td></tr><tr><td>Tian 2018</td><td>-14.08</td><td>20.8750</td><td></td><td>-14.08</td><td>[-54.99; 26.83]</td><td>0.1%</td><td>15.7%</td></tr><tr><td>Tian 2018</td><td>-36.48</td><td>54.0853</td><td></td><td>-36.48</td><td>[-142.49; 69.53]</td><td>0.0%</td><td>3.4%</td></tr><tr><td>Markopoulos 2005</td><td>4.00</td><td>75.9539</td><td></td><td>4.00</td><td>[-144.87; 152.87]</td><td>0.0%</td><td>1.8%</td></tr><tr><td>Fixed effect model</td><td></td><td></td><td></td><td>-32.06</td><td>[-33.08; -31.03]</td><td>100.0%</td><td>--</td></tr><tr><td>Random effects model</td><td></td><td></td><td></td><td>-19.21</td><td>[-39.47; 1.05]</td><td>--</td><td>100.0%</td></tr></table> <p>Heterogeneity: $I^2 = 72\%$, $\tau^2 = 244.7985$, $p < 0.01$</p>	Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)	Markopoulos 2009	-32.20	0.5232		-32.20	[-33.23; -31.17]	99.4%	43.6%	Tian 2018	-5.05	7.4871		-5.05	[-19.72; 9.62]	0.5%	35.5%	Tian 2018	-14.08	20.8750		-14.08	[-54.99; 26.83]	0.1%	15.7%	Tian 2018	-36.48	54.0853		-36.48	[-142.49; 69.53]	0.0%	3.4%	Markopoulos 2005	4.00	75.9539		4.00	[-144.87; 152.87]	0.0%	1.8%	Fixed effect model				-32.06	[-33.08; -31.03]	100.0%	--	Random effects model				-19.21	[-39.47; 1.05]	--	100.0%									
Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)																																																																			
Markopoulos 2009	-32.20	0.5232		-32.20	[-33.23; -31.17]	99.4%	43.6%																																																																			
Tian 2018	-5.05	7.4871		-5.05	[-19.72; 9.62]	0.5%	35.5%																																																																			
Tian 2018	-14.08	20.8750		-14.08	[-54.99; 26.83]	0.1%	15.7%																																																																			
Tian 2018	-36.48	54.0853		-36.48	[-142.49; 69.53]	0.0%	3.4%																																																																			
Markopoulos 2005	4.00	75.9539		4.00	[-144.87; 152.87]	0.0%	1.8%																																																																			
Fixed effect model				-32.06	[-33.08; -31.03]	100.0%	--																																																																			
Random effects model				-19.21	[-39.47; 1.05]	--	100.0%																																																																			

T. chol 6-mo	<table><thead><tr><th>Study</th><th>TE</th><th>seTE</th><th>Mean Difference</th><th>MD</th><th>95%-CI</th><th>Weight (fixed)</th><th>Weight (random)</th></tr></thead><tbody><tr><td>Atalay 2004</td><td>-6.96</td><td>14.0377</td><td></td><td>-6.96</td><td>[-34.47; 20.55]</td><td>0.1%</td><td>5.5%</td></tr><tr><td>Markopoulos 2009</td><td>11.50</td><td>0.3855</td><td></td><td>11.50</td><td>[10.74; 12.26]</td><td>96.5%</td><td>26.5%</td></tr><tr><td>Tian 2018</td><td>7.66</td><td>11.3567</td><td></td><td>7.66</td><td>[-14.60; 29.92]</td><td>0.1%</td><td>7.6%</td></tr><tr><td>Tian 2018</td><td>-1.86</td><td>2.7576</td><td></td><td>-1.86</td><td>[-7.26; 3.54]</td><td>1.9%</td><td>23.1%</td></tr><tr><td>Tian 2018</td><td>2.71</td><td>4.0179</td><td></td><td>2.71</td><td>[-5.16; 10.58]</td><td>0.9%</td><td>20.2%</td></tr><tr><td>Markopoulos 2005</td><td>10.50</td><td>5.2862</td><td></td><td>10.50</td><td>[0.14; 20.86]</td><td>0.5%</td><td>17.2%</td></tr><tr><td>Fixed effect model</td><td></td><td></td><td></td><td>11.15</td><td>[10.40; 11.89]</td><td>100.0%</td><td>--</td></tr><tr><td>Random effects model</td><td></td><td></td><td></td><td>5.16</td><td>[-2.07; 12.40]</td><td>--</td><td>100.0%</td></tr></tbody></table> <p>Heterogeneity: $I^2 = 83\%$, $\tau^2 = 51.3634$, $p < 0.01$</p>	Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)	Atalay 2004	-6.96	14.0377		-6.96	[-34.47; 20.55]	0.1%	5.5%	Markopoulos 2009	11.50	0.3855		11.50	[10.74; 12.26]	96.5%	26.5%	Tian 2018	7.66	11.3567		7.66	[-14.60; 29.92]	0.1%	7.6%	Tian 2018	-1.86	2.7576		-1.86	[-7.26; 3.54]	1.9%	23.1%	Tian 2018	2.71	4.0179		2.71	[-5.16; 10.58]	0.9%	20.2%	Markopoulos 2005	10.50	5.2862		10.50	[0.14; 20.86]	0.5%	17.2%	Fixed effect model				11.15	[10.40; 11.89]	100.0%	--	Random effects model				5.16	[-2.07; 12.40]	--	100.0%		
Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)																																																																				
Atalay 2004	-6.96	14.0377		-6.96	[-34.47; 20.55]	0.1%	5.5%																																																																				
Markopoulos 2009	11.50	0.3855		11.50	[10.74; 12.26]	96.5%	26.5%																																																																				
Tian 2018	7.66	11.3567		7.66	[-14.60; 29.92]	0.1%	7.6%																																																																				
Tian 2018	-1.86	2.7576		-1.86	[-7.26; 3.54]	1.9%	23.1%																																																																				
Tian 2018	2.71	4.0179		2.71	[-5.16; 10.58]	0.9%	20.2%																																																																				
Markopoulos 2005	10.50	5.2862		10.50	[0.14; 20.86]	0.5%	17.2%																																																																				
Fixed effect model				11.15	[10.40; 11.89]	100.0%	--																																																																				
Random effects model				5.16	[-2.07; 12.40]	--	100.0%																																																																				
T. chol 12-mo	<table><thead><tr><th>Study</th><th>TE</th><th>seTE</th><th>Mean Difference</th><th>MD</th><th>95%-CI</th><th>Weight (fixed)</th><th>Weight (random)</th></tr></thead><tbody><tr><td>Markopoulos 2009</td><td>14.40</td><td>0.3442</td><td></td><td>14.40</td><td>[13.73; 15.07]</td><td>52.6%</td><td>23.5%</td></tr><tr><td>Tian 2018</td><td>7.85</td><td>11.6384</td><td></td><td>7.85</td><td>[-14.96; 30.66]</td><td>0.0%</td><td>8.9%</td></tr><tr><td>Tian 2018</td><td>2.17</td><td>3.2172</td><td></td><td>2.17</td><td>[-4.14; 8.48]</td><td>0.6%</td><td>20.9%</td></tr><tr><td>Tian 2018</td><td>-0.62</td><td>0.9192</td><td></td><td>-0.62</td><td>[-2.42; 1.18]</td><td>7.4%</td><td>23.3%</td></tr><tr><td>Markopoulos 2005</td><td>1.00</td><td>0.3981</td><td></td><td>1.00</td><td>[0.22; 1.78]</td><td>39.3%</td><td>23.5%</td></tr><tr><td>Fixed effect model</td><td></td><td></td><td></td><td>7.94</td><td>[7.45; 8.43]</td><td>100.0%</td><td>--</td></tr><tr><td>Random effects model</td><td></td><td></td><td></td><td>4.62</td><td>[-4.00; 13.24]</td><td>--</td><td>100.0%</td></tr></tbody></table> <p>Heterogeneity: $I^2 = 99\%$, $\tau^2 = 82.2208$, $p < 0.01$</p>	Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)	Markopoulos 2009	14.40	0.3442		14.40	[13.73; 15.07]	52.6%	23.5%	Tian 2018	7.85	11.6384		7.85	[-14.96; 30.66]	0.0%	8.9%	Tian 2018	2.17	3.2172		2.17	[-4.14; 8.48]	0.6%	20.9%	Tian 2018	-0.62	0.9192		-0.62	[-2.42; 1.18]	7.4%	23.3%	Markopoulos 2005	1.00	0.3981		1.00	[0.22; 1.78]	39.3%	23.5%	Fixed effect model				7.94	[7.45; 8.43]	100.0%	--	Random effects model				4.62	[-4.00; 13.24]	--	100.0%										
Study	TE	seTE	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)																																																																				
Markopoulos 2009	14.40	0.3442		14.40	[13.73; 15.07]	52.6%	23.5%																																																																				
Tian 2018	7.85	11.6384		7.85	[-14.96; 30.66]	0.0%	8.9%																																																																				
Tian 2018	2.17	3.2172		2.17	[-4.14; 8.48]	0.6%	20.9%																																																																				
Tian 2018	-0.62	0.9192		-0.62	[-2.42; 1.18]	7.4%	23.3%																																																																				
Markopoulos 2005	1.00	0.3981		1.00	[0.22; 1.78]	39.3%	23.5%																																																																				
Fixed effect model				7.94	[7.45; 8.43]	100.0%	--																																																																				
Random effects model				4.62	[-4.00; 13.24]	--	100.0%																																																																				
Comparison with tamoxifen																																																																											
HDL 6-mo	<table><thead><tr><th rowspan="2">Study</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Mean Difference</th><th rowspan="2">MD</th><th rowspan="2">95%-CI</th><th rowspan="2">Weight (fixed)</th><th rowspan="2">Weight (random)</th></tr><tr><th>Total Mean</th><th>SD</th><th>Total Mean</th><th>SD</th></tr></thead><tbody><tr><td>Atalay 2004</td><td>36</td><td>-2.71</td><td>2.4540</td><td>36</td><td>5.41</td><td>4.5102</td><td>-8.12</td><td>[-9.80; -6.44]</td><td>3.1%</td><td>49.5%</td></tr><tr><td>Markopoulos 2005</td><td>90</td><td>-2.00</td><td>0.8454</td><td>86</td><td>-2.70</td><td>1.1414</td><td>0.70</td><td>[0.40; 1.00]</td><td>96.9%</td><td>50.5%</td></tr><tr><td>Fixed effect model</td><td>126</td><td></td><td></td><td>122</td><td></td><td></td><td>0.43</td><td>[0.14; 0.72]</td><td>100.0%</td><td>--</td></tr><tr><td>Random effects model</td><td></td><td></td><td></td><td></td><td></td><td></td><td>-3.67</td><td>[-12.31; 4.97]</td><td>--</td><td>100.0%</td></tr></tbody></table> <p>Heterogeneity: $I^2 = 99\%$, $\tau^2 = 38.5247$, $p < 0.01$</p>	Study	Experimental		Control		Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)	Total Mean	SD	Total Mean	SD	Atalay 2004	36	-2.71	2.4540	36	5.41	4.5102	-8.12	[-9.80; -6.44]	3.1%	49.5%	Markopoulos 2005	90	-2.00	0.8454	86	-2.70	1.1414	0.70	[0.40; 1.00]	96.9%	50.5%	Fixed effect model	126			122			0.43	[0.14; 0.72]	100.0%	--	Random effects model							-3.67	[-12.31; 4.97]	--	100.0%																
Study	Experimental		Control		Mean Difference	MD						95%-CI	Weight (fixed)	Weight (random)																																																													
	Total Mean	SD	Total Mean	SD																																																																							
Atalay 2004	36	-2.71	2.4540	36	5.41	4.5102	-8.12	[-9.80; -6.44]	3.1%	49.5%																																																																	
Markopoulos 2005	90	-2.00	0.8454	86	-2.70	1.1414	0.70	[0.40; 1.00]	96.9%	50.5%																																																																	
Fixed effect model	126			122			0.43	[0.14; 0.72]	100.0%	--																																																																	
Random effects model							-3.67	[-12.31; 4.97]	--	100.0%																																																																	



HDL 12-mo





LDL 6-mo





LDL 12-mo





TG 6-mo



TG 12-mo



T. chol 6-mo



T. chol 12-mo

Study	Experimental			Control			Mean Difference	MD	95%-CI	Weight	
	Total	Mean	SD	Total	Mean	SD				(fixed)	(random)
Markopoulos 2009	211	14.40	0.3442	200	21.60	0.2899		-7.20	[-7.26; -7.14]	99.9%	50.0%
Markopoulos 2005	90	1.00	0.3981	86	-20.00	7.9613		-21.00	[19.32; 22.68]	0.1%	50.0%
Fixed effect model	301			286				-7.16	[-7.22; -7.10]	100.0%	--
Random effects model								-7.16	[-20.75; 34.52]	--	100.0%

Heterogeneity: $I^2 = 100\%$, $\tau^2 = 397.2501$, $p < 0.01$

